EQUITY RESEARCH MEMO
Telos Biotech
Generated 5/5/2026
Executive Summary
Conviction (model self-assessment)65/100
Telos Biotech is a San Diego-based biotechnology company addressing a critical bottleneck in cell therapy: telomere attrition during ex-vivo manufacturing. Its proprietary Telovance™ protein complex safely elongates telomeres in therapeutic cells, enhancing their replicative lifespan and functional persistence. By overcoming the limited durability of engineered cells, Telovance™ could significantly improve outcomes in adoptive cell therapies such as CAR-T and T cell receptor therapies, potentially reducing the need for repeated infusions and lowering treatment costs.
Upcoming Catalysts (preview)
- Q3 2026Preclinical proof-of-concept data in CAR-T model70% success
- Q4 2026Series A financing round60% success
- Q1 2027Research partnership with cell therapy developer50% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)